Physician profile
Daniel Wong
NPI 1902002231
$5,739.95
in general payments reported to CMS, 2019-2025
22 companies · $2,671 in 2025
The $2,671 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $507 · 2022: $187 · 2023: $724 · 2024: $928 · 2025: $2,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,323.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $914.76 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $783.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $711.48 | 2019-2025 | Afrezza |
| Medtronic, INC. | $408.51 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $395.66 | 2020-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $330.87 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $316.28 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $314.80 | 2019-2025 | Omnipod, Omnipod |
| Beta Bionics, INC. | $306.82 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $301.70 | 2019-2025 | Korlym |
| Abbott Laboratories | $167.58 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $152.76 | 2024-2025 | Zepbound, Jardiance |
| Dexcom, INC. | $136.17 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $113.68 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $78.29 | 2025 | Isturisa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $66.14 | 2025 | |
| Ucb, INC. | $56.52 | 2024-2025 | Bimzelx, Cimzia |
| Sequel Med Tech, LLC | $52.61 | 2025 | Twiist |
| Baxter Healthcare | $50.97 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Averitas Pharma INC. | $32.28 | 2025 | Qutenza |
| Ascensia Diabetes Care US INC. | $31.65 | 2025 | |
| Astellas Pharma US INC | $16.53 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.